



24 February 2017

Sydney, Australia

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operations Office:

Suite 3 Level 4
828 Pacific Hwy
Gordon NSW 2072
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

Noxopharm Presentation and Interview

ASX The CEO Sessions February 2017

Noxopharm Limited (ASX:NOX) CEO Dr Graham Kelly was invited to present at the ASX FNN CEO Sessions on February 21, 2017.

Dr Kelly presented an update on the Company's clinical program and the anticipated news flow in 2017.

The presentation and an associated interview can be viewed using the following links:

Presentation

<http://www.finnewsnetwork.com.au/MediaCenter/AsxMediaCenter.aspx?Site=FNN890>

Interview

<http://www.finnewsnetwork.com.au/MediaCenter/AsxMediaCenter.aspx?Site=FNN878>

The session will also be available on the Company's page on the ASX website.

About NOX66

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to protect idronoxil from being inactivated in the human body by Phase 2 metabolism. The purpose is to ensure that most idronoxil administered remains in an active form rather than as inactive Phase 2 metabolites.

Idronoxil works by cancelling mechanisms (such as PARP1/Akt) in cancer cells that allow those cells to resist the killing effects of chemotherapies and radiotherapy. Idronoxil targets an external NADH oxidase, ENOX 2, responsible for maintaining the transmembrane electron potential (TMEP) in the plasma membrane. Inhibition of this enzyme causes loss of TMEP and disruption of key downstream pro-survival mechanisms including PARP1/Akt/PI3 kinase. ENOX2 is an oncogene whose expression is restricted to cancer cells.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Melbourne. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

INVESTOR AND MEDIA ENQUIRIES: Prue Kelly

E: info@noxopharm.com T: + 61 2 9144 2223

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.